Tildrakizumab was approved by FDA in 2018 for
Tildrakizumab was approved by FDA in 2018 to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
Cystic fibrosis
Migraine
Hypeension
Psoriasis
All India exam